New Medical Powder Stops Bleeding in 60 Seconds
The startup Miraqules won the SLINGSHOT 2026 competition for its trauma-care material, which is currently in the research stage.
Updated on Oct. 29, 2026 in Materials Science
Live Poll
Do you believe startup innovations are effectively improving healthcare outcomes in your country?
Indian startup Miraqules has secured the top prize at the SLINGSHOT 2026 competition in Singapore. The company was recognized for a new powder engineered to stop bleeding in 60 seconds.
Why it matters
The win highlights the global competitive landscape for emergency medical materials, emerging from a pool of over 5,000 international startups. The development marks a milestone for rapid-response trauma care technologies being showcased at the Singapore Week of Innovation and Technology.
The startup developed a specialized powder capable of arresting hemorrhaging within 60 seconds. This performance is evaluated against the backdrop of the SLINGSHOT 2026 field, which drew over 5,000 entrants.
The players
Miraqules
An Indian startup focused on medical materials, specifically rapid-action hemostatic agents for trauma care.
Enterprise Singapore
The government agency responsible for organizing the SLINGSHOT competition and fostering the Singapore startup ecosystem.
The details
The technology centers on a hemostatic powder, a substance designed to accelerate blood clotting and stop bleeding upon application. Miraqules secured the top position at the tenth annual SLINGSHOT event by demonstrating the efficacy of this material in a competitive field. The process involves the rapid physical interaction of the powder with blood at the wound site, though specific details regarding the material's internal mechanism remain proprietary or research-stage.
Timeline
The SLINGSHOT 2026 competition concluded in October 2026.
The Tech Race
This win at SLINGSHOT 2026 positions Miraqules within a broader international push to optimize first-aid trauma materials for speed. It marks a departure from traditional gauze-based methods by offering a powder-based solution that claims to minimize blood loss to a 60-second window.
The technology is currently a competition-winning project, meaning it is not yet available for purchase or clinical use by healthcare providers. Development and regulatory approval timelines for medical powders remain to be determined before they can reach emergency responder kits.
The takeaway
The win demonstrates growing investor interest in rapid-response trauma materials that can stabilize patients in under a minute. Watch for future clinical trial data or certification filings from the startup as it attempts to bring the powder from the laboratory to the field.
Further reading
For more on advancements in specialized materials, visit our Materials Science section.
Source note: This article includes information reported by CNA.
Live Poll
Do you believe startup innovations are effectively improving healthcare outcomes in your country?
